Related Experiment Video

Updated: Aug 19, 2026

Isolation of Neonatal Extrahepatic Cholangiocytes
07:54

Isolation of Neonatal Extrahepatic Cholangiocytes

Published on: June 5, 2014

Pediatric hepatobiliary disease

Qian Yuan1, Maureen M Jonas

  • 1Division of Gastroenterology and Nutrition, Children's Hospital, Boston, Massachusetts 02115, USA.

Current Opinion in Gastroenterology
|February 11, 2005
PubMed

Insights

This review highlights key advances in pediatric hepatobiliary diseases, covering diagnosis and prognosis for conditions like biliary atresia and hepatitis B.

Area of Science:

  • Pediatric Hepatology
  • Gastroenterology
  • Immunology

Background:

  • Pediatric hepatobiliary diseases pose significant health challenges.
  • Understanding disease mechanisms is crucial for improving outcomes.
  • Early diagnosis and prognosis prediction are vital for effective management.

Purpose of the Study:

  • To review recent major advances in pediatric hepatobiliary disease.
  • To cover key areas including extrahepatic biliary atresia, cystic fibrosis-related liver disease, liver transplantation outcomes, acetaminophen hepatotoxicity, chronic hepatitis B, hepatocellular carcinoma, and neonatal lupus erythematosus.

Main Methods:

  • Literature review of recent publications.
  • Synthesis of findings across seven distinct areas of pediatric hepatobiliary disease.

Main Results:

  • Significant progress has been made in understanding disease mechanisms.
  • New insights offer potential for earlier diagnosis and improved prognosis prediction.
  • Advances span diverse conditions from biliary atresia to neonatal lupus erythematosus.

Conclusions:

  • Recent advances provide valuable tools for managing pediatric hepatobiliary diseases.
  • Continued research is essential for further improving patient care and outcomes.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...